Concise Prescribing Info
HIV infection.
Dosage/Direction for Use
Adult: PO Combined w/ other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days.
May be taken with or without food.
Hypersensitivity. Lactation. Severe hepatic impairment.
Special Precautions
Pregnancy. Interrupt treatment if severe hepatotoxicity or life-threatening skin reactions develop. Renal or hepatic insufficiency. Monitor liver function periodically.
Adverse Reactions
Skin rash, nausea, vomiting, headache, abnormal LFT, fatigue, diarrhoea, abdominal pain.
Potentially Fatal: Severe and life-threatening hepatotoxic and skin reactions.
Drug Interactions
Mutually increased levels effects when used with drugs extensively metabolised by CYP3A. Reduced levels/effects of methadone.
CIMS Class
ATC Classification
J05AG01 - nevirapine ; Belongs to the class of non-nucleoside reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on nevirapine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in